Ameriprise’s Ginkgo Bioworks DNA Stock Holding History

Ameriprise’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$253K	Sell	41,199 -8,079	-16%	-$67.2K	﹤0.01%	3810
2025 Q4	$410K	Buy	+49,278	New	+$531K	﹤0.01%	3698
2024 Q3	–	Sell	-807	Closed	-$10.8K	–	3952
2024 Q2	$10.8K	Sell	807 -1,004	-55%	-$30K	﹤0.01%	3850
2024 Q1	$84K	Sell	1,811 -313	-15%	-$16.2K	﹤0.01%	3790
2023 Q4	$144K	Sell	2,124 -8	-0.4%	-$490	﹤0.01%	3771
2023 Q3	$154K	Sell	2,132 -585	-22%	-$46.8K	﹤0.01%	3730
2023 Q2	$202K	Sell	2,717 -44	-2%	-$2.6K	﹤0.01%	3727
2023 Q1	$147K	Buy	2,761 +461	+20%	+$29.2K	﹤0.01%	3787
2022 Q4	$155K	Sell	2,300 -261	-10%	-$24K	﹤0.01%	3749
2022 Q3	$320K	Buy	2,561 +2,143	+513%	+$255K	﹤0.01%	3560
2022 Q2	$40K	Buy	+418	New	+$51K	﹤0.01%	3835

Other funds holding DNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise's DNA Position: Q1 2026 in Review

Ameriprise reduced its Ginkgo Bioworks (DNA) stake by 16% in Q1 2026, selling an estimated $67.2K and leaving 41,199 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #3810.

Ameriprise first reported a position in DNA in Q2 2022 and has held it in 11 quarters since. The position peaked at $410K in Q4 2025. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

Ameriprise held 41,199 shares of Ginkgo Bioworks worth $253K as of Q1 2026.
Ameriprise sold 8,079 Ginkgo Bioworks shares in Q1 2026, an estimated $67.2K.
Ginkgo Bioworks made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3810 holding.
Ameriprise first reported a position in Ginkgo Bioworks in Q2 2022 and has held it in 11 quarters since.
Ameriprise's Ginkgo Bioworks position peaked at $410K in Q4 2025.
174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.